Latest Breaking News On - Astrazeneca rare - Page 1 : comparemela.com

CENTOGENE Biodatabank Grows to Incorporate Disease Insights

CENTOGENE Biodatabank Grows to Incorporate Disease Insights
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomLennart streibelMelissa hallKim strattonMichaelj fox foundationDrug administrationExchange commissionCorporate communicationsChief executive officerLysosomal storage disordersAstrazeneca rareInsight reports

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomLennart streibelMelissa hallKim strattonExchange commissionDrug administrationMichaelj fox foundationCorporate communicationsChief executive officerLysosomal storage disordersAstrazeneca rareInsight reports

Often misdiagnosed, it s time to raise awareness of the rare disease amyloidosis

(BPT) - What started as a dream trip to Hawaii became a medical turning point for Sally Cox. While snorkeling in the crystal-clear waters, she suddenly found it difficult to

United statesSally coxMichael laneRare disease unitAstrazeneca rare

BridgeBio Pharma (BBIO) Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients

BridgeBio Pharma (BBIO) Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Eidos therapeutics incBridgebio pharma incBridgebio pharmaJapan phaseAstrazeneca rareAstrazeneca rare diseaseEidos therapeutics

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality.

Vikram baliBio pharma incSecurities exchangeExchange commissionBridgebio pharma incEidos therapeutics incAstrazeneca rare diseaseWin ratioBio pharmaJapan phaseAstrazeneca rareEidos therapeuticsBridgebio pharmaSecurities actSecurities exchange actExchange act